Physician profile
Amine Bourbia
NPI 1295141927
$16,039.50
in general payments reported to CMS, 2019-2025
37 companies · $1,211 in 2025
The $1,211 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $989 · 2020: $356 · 2021: $1,361 · 2022: $8,989 · 2023: $1,686 · 2024: $1,448 · 2025: $1,211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,621 · Travel and Lodging: $689 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,621.31 |
| Travel and Lodging | $689.23 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $8,328.95 | 2021-2024 | Da Vinci Surgical System |
| Glaxosmithkline, LLC. | $1,356.34 | 2020-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,021.21 | 2020-2025 | Breztri, Fasenra, Airsupra |
| Boston Scientific Corporation | $988.81 | 2019 | |
| Olympus Corporation of The Americas | $689.23 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $505.44 | 2020-2024 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $472.61 | 2020-2024 | Ofev |
| Mylan Specialty L.P. | $319.33 | 2020-2024 | Yupelri |
| Grifols USA, LLC | $254.88 | 2022-2024 | Prolastin-C Liquid |
| Genzyme Corporation | $224.69 | 2021-2024 | |
| Amgen INC. | $184.11 | 2022-2025 | Tezspire |
| Insmed, INC. | $176.42 | 2020-2024 | Arikayce |
| Takeda Pharmaceuticals U.S.A., INC. | $165.95 | 2022-2024 | Glassia |
| Olympus America INC. | $146.78 | 2025 | Spiration Valve System |
| United Therapeutics Corporation | $143.11 | 2020-2024 | Tyvaso, Orenitram, Remodulin |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galvanize Therapeutics, INC | $113.99 | 2025 | Aliya System |
| Ani Pharmaceuticals, INC. | $111.76 | 2023-2024 | Purified Cortrophin Gel |
| Harmony Biosciences LLC | $101.94 | 2023-2024 | Wakix |
| Sanofi-Aventis U.S. LLC | $96.50 | 2022 | |
| Abbvie INC. | $78.86 | 2021-2023 | Teflaro, Avycaz |
| Merck Sharp & Dohme LLC | $74.27 | 2023-2024 | Winrevair |
| Regeneron Healthcare Solutions, INC. | $71.43 | 2023-2024 | Dupixent |
| Novartis Pharmaceuticals Corporation | $50.89 | 2021-2023 | |
| Pfizer INC. | $41.04 | 2022-2023 | |
| Mallinckrodt Hospital Products INC. | $37.57 | 2023 | Acthar |
| Philips North America LLC | $32.36 | 2023 | |
| Jazz Pharmaceuticals INC. | $29.90 | 2021 | |
| Allergan, INC. | $28.77 | 2020 | |
| Axsome Therapeutics, INC. | $28.61 | 2024 | Sunosi |
| Baxter Healthcare | $28.16 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Gilead Sciences, INC. | $25.70 | 2023 | |
| Johnson & Johnson Health Care Systems INC. | $21.96 | 2023 | Uptravi |
| Sunovion Pharmaceuticals INC. | $19.57 | 2021 | |
| Inspire Medical Systems, INC. | $19.13 | 2023 | Inspire |
| Tactile Systems Technology INC | $18.33 | 2023 | Entre Plus, Flexitouch Plus |
| Inogen, INC. | $16.84 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Alexion Pharmaceuticals, INC. | $14.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amine Bourbia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.